Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. more
Time Frame | ELDN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.83% | -3.39% | 0.2% |
1-Month Return | 15.38% | -1.92% | 2.72% |
3-Month Return | 78.57% | -10.54% | 7.31% |
6-Month Return | 59.57% | -4.47% | 10.44% |
1-Year Return | 190.32% | 4.06% | 27.53% |
3-Year Return | -5.06% | 0.94% | 30.88% |
5-Year Return | -51.92% | 36.67% | 89.21% |
10-Year Return | -99.81% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 120.00K | 120.00K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 182.00K | 183.00K | 195.00K | 373.00K | 374.00K | [{"date":"2019-12-31","value":48.66,"profit":true},{"date":"2020-12-31","value":48.93,"profit":true},{"date":"2021-12-31","value":52.14,"profit":true},{"date":"2022-12-31","value":99.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (182.00K) | (63.00K) | 120.00K | (373.00K) | (374.00K) | [{"date":"2019-12-31","value":-151.67,"profit":false},{"date":"2020-12-31","value":-52.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-310.83,"profit":false},{"date":"2023-12-31","value":-311.67,"profit":false}] |
Gross Margin | - | (52.50%) | 100.00% | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-52.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 14.18M | 16.18M | 36.87M | 39.78M | 42.63M | [{"date":"2019-12-31","value":33.28,"profit":true},{"date":"2020-12-31","value":37.97,"profit":true},{"date":"2021-12-31","value":86.49,"profit":true},{"date":"2022-12-31","value":93.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (16.05M) | (18.46M) | (36.87M) | 8.49M | (43.00M) | [{"date":"2019-12-31","value":-188.95,"profit":false},{"date":"2020-12-31","value":-217.36,"profit":false},{"date":"2021-12-31","value":-433.98,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-506.18,"profit":false}] |
Total Non-Operating Income/Expense | - | (9.58M) | 7.00K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-136842.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (16.01M) | (23.21M) | (36.86M) | (87.97M) | (40.33M) | [{"date":"2019-12-31","value":-1601100000,"profit":false},{"date":"2020-12-31","value":-2321500000,"profit":false},{"date":"2021-12-31","value":-3686000000,"profit":false},{"date":"2022-12-31","value":-8796600000,"profit":false},{"date":"2023-12-31","value":-4032600000,"profit":false}] |
Income Taxes | 1.87M | (404.00K) | (2.35M) | (462.00K) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-21.64,"profit":false},{"date":"2021-12-31","value":-126.08,"profit":false},{"date":"2022-12-31","value":-24.75,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (22.81M) | (34.51M) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2281100000,"profit":false},{"date":"2021-12-31","value":-3450600000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (16.01M) | (22.81M) | (34.51M) | (87.97M) | (89.08M) | [{"date":"2019-12-31","value":-1601100000,"profit":false},{"date":"2020-12-31","value":-2281100000,"profit":false},{"date":"2021-12-31","value":-3450600000,"profit":false},{"date":"2022-12-31","value":-8796600000,"profit":false},{"date":"2023-12-31","value":-8908400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.88M) | (22.81M) | (34.51M) | (87.50M) | (40.33M) | [{"date":"2019-12-31","value":-1787800000,"profit":false},{"date":"2020-12-31","value":-2281100000,"profit":false},{"date":"2021-12-31","value":-3450600000,"profit":false},{"date":"2022-12-31","value":-8750400000,"profit":false},{"date":"2023-12-31","value":-4032600000,"profit":false}] |
EPS (Diluted) | (22.86) | (13.21) | (2.32) | (2.76) | (1.79) | [{"date":"2019-12-31","value":-2286,"profit":false},{"date":"2020-12-31","value":-1321,"profit":false},{"date":"2021-12-31","value":-232,"profit":false},{"date":"2022-12-31","value":-276,"profit":false},{"date":"2023-12-31","value":-179,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ELDN | |
---|---|
Cash Ratio | 6.26 |
Current Ratio | 6.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ELDN | |
---|---|
ROA (LTM) | -33.36% |
ROE (LTM) | -25.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ELDN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ELDN | |
---|---|
Trailing PE | 6.16 |
Forward PE | 5.39 |
P/S (TTM) | 0.00 |
P/B | 3.53 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.84 |
Eledon Pharmaceuticals Inc (ELDN) share price today is $4.325
Yes, Indians can buy shares of Eledon Pharmaceuticals Inc (ELDN) on Vested. To buy Eledon Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ELDN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eledon Pharmaceuticals Inc (ELDN) via the Vested app. You can start investing in Eledon Pharmaceuticals Inc (ELDN) with a minimum investment of $1.
You can invest in shares of Eledon Pharmaceuticals Inc (ELDN) via Vested in three simple steps:
The 52-week high price of Eledon Pharmaceuticals Inc (ELDN) is $5.54. The 52-week low price of Eledon Pharmaceuticals Inc (ELDN) is $1.43.
The price-to-earnings (P/E) ratio of Eledon Pharmaceuticals Inc (ELDN) is 6.1644
The price-to-book (P/B) ratio of Eledon Pharmaceuticals Inc (ELDN) is 3.53
The dividend yield of Eledon Pharmaceuticals Inc (ELDN) is 0.00%
The market capitalization of Eledon Pharmaceuticals Inc (ELDN) is $268.83M
The stock symbol (or ticker) of Eledon Pharmaceuticals Inc is ELDN